Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) Interest & Investment Income (2019 - 2026)

InMed Pharmaceuticals has reported Interest & Investment Income over the past 5 years, most recently at $74379.0 for Q4 2025.

  • For Q4 2025, Interest & Investment Income rose 143.58% year-over-year to $74379.0; the TTM value through Dec 2025 reached $236396.0, down 24.41%, while the annual FY2025 figure was $155882.0, 70.47% down from the prior year.
  • Interest & Investment Income for Q4 2025 was $74379.0 at InMed Pharmaceuticals, down from $93765.0 in the prior quarter.
  • Over five years, Interest & Investment Income peaked at $166760.0 in Q4 2023 and troughed at $5148.0 in Q3 2021.
  • A 5-year average of $80025.4 and a median of $73483.0 in 2022 define the central range for Interest & Investment Income.
  • Biggest five-year swings in Interest & Investment Income: surged 1310.0% in 2022 and later plummeted 86.36% in 2025.
  • Year by year, Interest & Investment Income stood at $26277.0 in 2021, then skyrocketed by 340.68% to $115797.0 in 2022, then soared by 44.01% to $166760.0 in 2023, then tumbled by 81.69% to $30536.0 in 2024, then skyrocketed by 143.58% to $74379.0 in 2025.
  • Business Quant data shows Interest & Investment Income for INM at $74379.0 in Q4 2025, $93765.0 in Q3 2025, and $51687.0 in Q2 2025.